Who’s Here
Who’s Here
Our tenants themselves are a cluster of biology and chemistry-based businesses, working across multiple disciplines within life sciences, from drug discovery to diagnostics to digital health.
3D Bio-Tissues spun-out of Newcastle University in 2019, and their current focus is to develop corneal, muscle and skin tissue equivalents from human and animal cells, to bypass the need for synthetic materials. Their technology is the outcome of more than 20 years of pioneering research and works by applying novel bio-inspired manufacturing processes to generate complex structures. The team’s goal is to create structured, functional, and scalable bio-equivalent tissues for both clinical and industrial use. Their lead product is a human derived corneal tissue product that aims to address the chronic world-wide shortage of sight-saving donor corneas
Alcyomics is a Newcastle based unique pre-clinical service provider using Skimune®, non-artificial human skin explants for predicting adverse immune reactions as well as determining efficacy of novel compounds including pharmaceuticals, chemicals and cosmetics.
Their mission at Alcyomics is to provide novel solutions for pre-clinical drug safety and efficacy testing for therapeutics including cellular therapies which is also extended to the chemical and cosmetic industries. As a Service provider Alcyomics aspires to take the lead in providing unique screening services using human in vitro skin explant assays enabling more cost-effective commercialisation of products and or drugs. Alcyomics development pipeline includes drug discovery disease modelling for the identification of novel drug targets.
They also offer a consultancy service of how the pre-clinical data can be used to assist clinical trial development such as dose response and assist in developing stratified medicine/ precision medicine approaches to patient selection. Alcyomics technology is also a reliable alternative to animal testing for safety and potency assessment of novel compounds.
AMLo Biosciences was founded in 2017 by a team with an internationally acclaimed track record of melanoma research, identification of translational biomarkers, drug discovery and development of biotech companies.
AMLo Biosciences is translating ground-breaking research in cancer biomarkers into a revolutionary range of prognostic and companion diagnostic products to improve patient outcomes and reduce the financial burden of cancers on global healthcare economies. These new prognostic tests will better identify a patient’s true risk of disease progression, so that individuals can be counselled and treated appropriately, and precious healthcare resources can be targeted effectively to the patients who need it most.
Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping.
We use alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipment. We can hold cells and tissues at room temperature for up to two weeks, effectively placing them into a state of hibernation.
BiBerChem are highly experienced in synthetic organic chemistry and medicinal chemistry, their medicinal chemists have been involved in several drug research projects with pharma and academic collaborators. Additionally, their company scientific director Professor Bernard T Golding has published more than 500 publications, his main research areas include synthetic methodology, enzyme mechanisms, drug design and mechanistic toxicology.
CellRev provides customers with a scalable adherent cell processing platform for research and manufacturing.
We provide high quality specialist lab services to researchers, academics, healthcare providers and industry.
Through our biobank we can provide access to three million clinical tissue samples – both archived and prospectively collected- and we use a range of cellular pathology techniques to identify disease in human tissue.
Our services include histology, molecular pathology and our state-of-the art equipment enables us to keep pace with innovative and effective techniques to help our clients improve their research.
We’re part of the cellular pathology team at Newcastle Hospitals and we work closely with hospital teams and departments including the North East Innovation Lab, to support clients’ research and diagnostic needs.
Find out more on our Website
ExplantLab combines advanced engineering analysis, cutting edge genetic technology and AI to improve medical device performance. It is the only independent lab in the United Kingdom where patients may have implants removed from their body (“explants”) analysed.
ExplantLab provides funding and technology for the NHS portfolio research project “The Northern Retrieval Registry (NRR)”.
Iksuda Therapeutics is a developer of next generation Antibody Drug Conjugates (ADCs) for the treatment of difficult to treat solid tumours. Iksuda’s portfolio is centred on its proprietary conjugation chemistry, PermaLink® which, by leveraging its unrivalled stability profile, has allowed the company to access a range of tuneable, ultra-potent payloads, with the goal of significantly improving the therapeutic index of this important modality in the treatment of cancer.
The company is currently advancing its lead candidate IKS01, a Folate Receptor targeting ADC, which demonstrates significant clinical differentiation and plan to enter clinical trials in 2021. The company continues to build a broader, clinically differentiated portfolio of ADCs and anticipates nominating its second target for pre-clinical/clinical development in 2020.
Jiahua is a leading independent Chinese Specialty Chemicals manufacturing group. The HQ and R & D Centre are based in Shanghai. The main industries currently supplied are Urethanes, Surfactants and Construction Chemicals. They have offices and China, Dubai, Philadelphia and Newcastle.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. Their mission is to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Newcells Biotech develops in vitro cell based assays for drug discovery and development. Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology and organoid technology to build models that incorporate the “best biology” for predicting in vivo behaviour of new drugs and actives.
Our experts have developed and launched assays to measure transporter function, safety and efficacy in a range of cell and tissue types, including kidney and retina. We have the capability to develop and implement in vitro protocols to measure drug transport in the kidney, assess nephrotoxicity, retinal toxicity and model disease using human and a range of preclinical species.
NewChem is an innovative chemical company which specialises in commercial applications for organic chemistry. NewChem Technologies works with industry and academia to develop and deliver new breakthrough products in synthetic chemistry.
They work with a wide variety of companies in fields ranging from pharmaceuticals, diagnostics, biotechnology, veterinary science and agrochemicals. They emerged as a spin-out from Newcastle University School of Chemistry and retains the culture of curiosity and intellectual enquiry inherited from our academic roots.
We are part of Newcastle Hospitals and work with UK and international clients around the globe to support the development of cutting-edge diagnostics.
Our scientists work with organisations of all sizes, from university spin outs to large companies, to accelerate the advancement and use of the most innovative diagnostics.
We offer a wide range of services, covering everything needed to scientifically evaluate and validate new products and technologies, including access to a large biobank of clinical samples.
Our work began with Covid-19 diagnostics and has since expanded to other virus and health threats, such as sepsis and cancers.
https://commercial.newcastle-hospitals.nhs.uk/our-services/innovation-lab/
Get in contact – nuth.enquiries.innovationlab@nhs.net
Case studies
- AMLo Biosciences: Cancer diagnostics spin-out amplifies position in Newcastle’s life science clusterMichelle Maley2020-11-20T17:01:55+00:00
- Atelerix: A university spin out who wanted to be part of our hub of biotech companiesadmin2020-08-05T14:23:09+00:00
- AMLo Biosciences: Cancer diagnostics spin-out amplifies position in Newcastle’s life science clusterMichelle Maley2020-11-20T17:01:55+00:00
- Atelerix: A university spin out who wanted to be part of our hub of biotech companiesadmin2020-08-05T14:23:09+00:00